Liver injury resulting from hepatitis C infection.
Comprehensive, easy-to-understand information about this condition
How we create this content →Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Feb 5, 2026
AI-Generated Content: This summary was generated using AI. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning hepatitis C induced liver cirrhosis
Updated Jan 29, 2026
AgomAb Therapeutics, a Belgian biotech focused on TGFβ inhibitors for fibrotic diseases, is set to raise $200 million through its IPO, offering 12.5 million shares priced between $15 and $17. The company is also developing a preclinical candidate for liver cirrhosis.
A CDC study reveals that over 60,000 patients in the U.S. were advised to get tested for hepatitis B and C due to lapses in infection control practices by healthcare personnel outside of hospitals. This highlights significant risks in patient safety and the need for improved adherence to infection protocols.
Acute viral hepatitis cases, specifically hepatitis A, B, and C, have significantly declined in the U.S. from 1995 to 2005, with hepatitis A and B reaching their lowest levels. This trend highlights the effectiveness of public health initiatives in managing these diseases.